About this pathway
Background
Desflurane, enflurane, halothane, isoflurane, methoxyflurane, and sevoflurane are fluorinated inhaled anesthetics contraindicated in patients with variants in RYR1 and CACNA1S see CPIC guideline for volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes [Article:30499100]. These genes and variants are involved with the pharmacodynamics side effects of the drugs. Halothane, and to a lesser degree the other volatile anesthetics, have been associated with fatal hepatic necrosis [Article:18509326]. It is generally considered that the extent of metabolism correlates with the toxicity: halothane being the most extensively metabolized, then methoxyflurane > sevoflurane > enflurane > isoflurane > desflurane [Article:8214760].
Metabolism
Estimated metabolism of enflurane is approximately 8% [Article:18509326]. Incidence of immune hepatitis for enflurane is low at around 1:300,000 compared to halothane at 1:20,000 [Article:18509326].
Reactions & interactions (3)
-
Biochemical Reaction
2-(difluoromethoxy)-2,2-difluoroacetyl fluoride → difluoromethoxydifluoroacetic acid + fluoride
-
Biochemical Reaction
enflurane → 2-(difluoromethoxy)-2,2-difluoroacetyl fluoride
-
Catalysis
CYP2E1 → Biochemical Reaction
Edit history (1)
- 2021-03-16 Create